# OnCo record sunshine-lake-pharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/sunshine-lake-pharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "sunshine-lake-pharma" ;
  schema:name "Sunshine Lake Pharma (HEC)"@en ;
  schema:alternateName "Sunshine Lake Pharma Co., Ltd."@en, "HEC Pharm"@en ;
  schema:description "Sunshine Lake Pharma, the pharmaceutical arm of China's HEC group based in Dongguan, is running phase 3 trials of clifutinib, a FLT3 inhibitor for acute myeloid leukaemia, and lerotinib in oesophageal cancer."@en ;
  schema:url <https://onco.cc/companies/sunshine-lake-pharma/>, <https://www.hec.cn/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.hec.cn/>, <https://clinicaltrials.gov/search?lead=Sunshine%20Lake%20Pharma> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/esophageal/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/clifutinib/>, <https://onco.cc/drugs/lerotinib/> ;
  onco:trials <https://onco.cc/trials/nct05586074/>, <https://onco.cc/trials/nct04415853/>, <https://onco.cc/trials/nct05133882/>, <https://onco.cc/trials/nct05451602/> .